Anteris Technologies Global Corp. Common Stock (AVR)

• Market cap: $214M
• 1 day: -0.50%
• 5 days: 2.05%
• 1 month: 8.17%
• 3 months: 8.36%
• 6 months: 8.36%
• Year to date: 7.39%
• 1 year: 8.36%
• 5 years: 8.36%
• 10 years: 8.36%

About: Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $9 51% upside
• Avg. target: $16.50 177% upside
• High target: $22 269% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Lake Street Frank Takkinen 63% 1-year accuracy 12 / 19 met price target	236% upside $20	Buy Initiated	8 Jan 2025
TD Cowen Joshua Jennings 48% 1-year accuracy 10 / 21 met price target	152% upside $15	Buy Initiated	7 Jan 2025
Cantor Fitzgerald Ross Osborn 51% 1-year accuracy 25 / 49 met price target	51% upside $9	Overweight Initiated	7 Jan 2025
Barclays Matt Miksic 73% 1-year accuracy 27 / 37 met price target	269% upside $22	Overweight Initiated	7 Jan 2025